The estimated Net Worth of Brian F. Sullivan is at least $50.4 Milion dollars as of 9 December 2022. Mr Sullivan owns over 260,869 units of Celcuity Inc stock worth over $46,878,632 and over the last 20 years he sold CELC stock worth over $3,242,447. In addition, he makes $250,000 as Co-Founder a Chairman & CEO at Celcuity Inc.
Mr has made over 17 trades of the Celcuity Inc stock since 2010, according to the Form 4 filled with the SEC. Most recently he bought 260,869 units of CELC stock worth $1,499,997 on 9 December 2022.
The largest trade he's ever made was buying 260,869 units of Celcuity Inc stock on 9 December 2022 worth over $1,499,997. On average, Mr trades about 6,969 units every 64 days since 2004. As of 9 December 2022 he still owns at least 3,016,643 units of Celcuity Inc stock.
You can see the complete history of Mr Sullivan stock trades at the bottom of the page.
Brian F. Sullivan is the Co-Founder, Chairman & CEO at Celcuity Inc.
As the Co-Founder a Chairman & CEO of Celcuity Inc, the total compensation of Mr Sullivan at Celcuity Inc is $250,000. There are 1 executives at Celcuity Inc getting paid more, with Dr. Lance G. Laing having the highest compensation of $333,900.
Mr Sullivan is 59, he's been the Co-Founder a Chairman & CEO of Celcuity Inc since . There are 3 older and 1 younger executives at Celcuity Inc. The oldest executive at Celcuity Inc is Dr. John R. MacDonald Ph., Dabt, 66, who is the Sr. VP of R&D.
Brian's mailing address filed with the SEC is 16305 36TH AVENUE NORTH, SUITE 100, MINNEAPOLIS, MN, 55446.
Over the last 7 years, insiders at Celcuity Inc have traded over $452,378 worth of Celcuity Inc stock and bought 317,370 units worth $2,387,116 . The most active insiders traders include Brian F. Sullivan, Richard Nigon a Polly A. Murphy. On average, Celcuity Inc executives and independent directors trade stock every 67 days with the average trade being worth of $147,164. The most recent stock trade was executed by Richard E Buller on 23 August 2024, trading 350 units of CELC stock currently worth $5,933.
celcuity is a biotech company developing state-of-the-art cell-based assays using our proprietary functional cellular analysis platform. we directly assess the functionality of the disease-related signaling pathways of a patient's diseased cells ex vivo to determine whether a drug therapy has the intended effect on those cells. the patient specific cellular data we provide offers clinicians and pharmaceutical companies unique insight into a patient's response to a drug therapy, and it will change the paradigm of personalized medicine.
Celcuity Inc executives and other stock owners filed with the SEC include: